ReviewInternational journal of molecular sciences2024
The Role of Tumor Biomarkers in Tailoring the Approach to Advanced Ovarian Cancer.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis.Future oncology (London, England) · 2025Pooled it
- Efficacy of PD-1/PDL-1 inhibitors for ovarian cancer: a systematic review and network meta-analysis.Future oncology (London, England) · 2025Pooled it
- The P7 peptide antagonizes bFGF-induced malignant behaviors of ovarian cancer by inhibiting MEK/ERK signaling pathway.Future science OA · 2026Article
- Predictive Features Specific to FIGO IIIA1 Ovarian Cancer: What Drives Prognosis.Annals of surgical oncology · 2026Review
- Prevalence of Homologous Recombination Deficiency and Treatment Patterns in Patients with Newly Diagnosed Advanced Ovarian Cancer in Bulgaria: A Real-World Cohort Study (VALIDATE).Medicina (Kaunas, Lithuania) · 2026Observational
- Prognostic Nomogram for Ovarian Cancer Patients on First-Line Maintenance Therapy With PARP Inhibitors: A Retrospective Cohort Study.Cancer medicine · 2026Article
- Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: results from HALO-Taiwan subset.Journal of gynecologic oncology · 2026Article
- Evaluation of drug options for epithelial ovarian cancer (EOC) treatment using the analytical hierarchy process improves decision-making transparency.Discover oncology · 2025Article
- Cancer-testis antigen ACRBP: Cytotoxic response to its HLA-A2 restricted peptide and immune features in ovarian cancer.Human vaccines & immunotherapeutics · 2025Article
- Prognostic significance of tumour-infiltrating T lymphocytes in ovarian cancer: a protocol for systematic review and meta-analysis.BMJ open · 2025Article
- Silent Threat: Delayed Brain Metastasis After Successful Ovarian Cancer Therapy.Clinical case reports · 2025Article
- The Expression and Clinical Significance of C1orf106 in Low-Grade Serous Ovarian Cancer.The journal of obstetrics and gynaecology research · 2025Article
- Clinicopathological Characteristics and Oncologic Outcomes of Endometrioid Ovarian Carcinoma: A Retrospective Study from a Tertiary Cancer Centre.Biomedicines · 2025Article
- Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study.Oncology and therapy · 2025Article
- Benign serous cystadenofibroma with multimodal imaging suggestive of malignancy in a symptomatic postmenopausal patient.Przeglad menopauzalny = Menopause review · 2025Article
- Redefining Risk, Biomarkers, and Precision Therapy for Hereditary Ovarian Cancer: A Review.ACS omega · 2025Review
- The -124C>T Mutation of theCurrent oncology (Toronto, Ont.) · 2025Article
- Bioinformatic RNA-Seq Functional Profiling of the Tumor Suppressor Gene OPCML in Ovarian Cancers: The Multifunctional, Pleiotropic Impacts of Having Three Ig Domains.Current issues in molecular biology · 2025Article
- Tumor Cell-Expressed Herpesvirus Entry Mediator Regulates Proliferation and Adaptive Immunity in Ovarian Cancer.Immunity, inflammation and disease · 2025Article
- A novel machine learning-driven immunogenic cell death signature for predicting ovarian cancer prognosis.Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing evidence has demonstrated the role of mutations of tumor biomarkers in diagnosing and treating epithelial ovarian cancer. This review aims to analyze recent literature on the correlation between tumor biomarkers and chemotherapy in nonmucinous ovarian cancer, providing suggestions for personalized treatment approaches. An extensive literature search was conducted to identify relevant studies and trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.